准电压通的质子通道HV1:优化了具有抗癌潜力的5--2-氨基胺醇
Martina Piga1, Geraldo Jorge Domingos2, Adam Feher2
1Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, Ljubljana, 1000, Slovenia.
European journal of medicinal chemistry
|July 15, 2025
概括
新的电压关闭质子通道 (HV1) 抑制剂在治疗癌症和神经炎症等疾病方面表现有前途. 优化的化合物表现出强大的抗增殖作用,特别是在具有高HV1表达的细胞中,推进治疗策略.
科学领域:
- 生物化学和药物化学 医学化学
- 离子通道生物学 离子通道生物学
- 药物发现 药物发现 药物发现
背景情况:
- 电压关闭的质子通道 (HV1) 与各种疾病有关,包括瘤,神经炎症,免疫系统疾病和不孕症.
- HV1 抑制剂代表了这些疾病的有前途的治疗途径.
研究的目的:
- 设计,合成和优化一系列针对HV1通道的基于5-phenyl-2-aminoimidazole的抑制剂.
- 评估这些新型抑制剂的功效,结构-活性关系,抗增殖作用和类似药物的特性.
主要方法:
- 优化5--2-氨基胺醇衍生物的合成.
- 在体外测试以确定HV1抑制的IC50值.
- 使用THP-1和MCF-7细胞系进行抗增殖试验.
- 对溶解度,血蛋白结合,透性,代谢稳定性和通道选择性的评估 (KV1.3,NaV1.5).
主要成果:
- 最强大的HV1抑制剂实现了低微分子IC50值.
- 结构分析显示,非替代的2-aminoimidazole核心和灵活的链接器对于通道结合的重要性.
- 与HV1-低MCF-7细胞相比,抑制剂对HV1-高THP-1细胞的疗效更大.
- 第二类化合物表现出更好的类似药物的特性 (溶解性,透性,代谢稳定性),但对其他离子通道的选择性有限.
结论:
- 这项研究成功地开发出基于5-phenyl-2-aminoimidazole的强效HV1抑制剂,具有有利的药物样性.
- 这些发现为研究HV1在疾病中的作用提供了有价值的化学工具.
- 这些抑制剂为开发针对HV1介导途径的新疗法奠定了基础.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
327
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
327
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
450
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
450
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Electron Transport Chain: Complex I and II
15.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
265
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
265
Targets for Drug Action: Overview
7.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.5K


